Literature DB >> 16206064

A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis.

Henry H Balfour1, Carol J Holman, Kristin M Hokanson, Meghan M Lelonek, Jill E Giesbrecht, Dana R White, David O Schmeling, Chiu-Ho Webb, Winston Cavert, David H Wang, Richard C Brundage.   

Abstract

BACKGROUND: Characterizing virus-host interactions during self-limited infectious mononucleosis could explain how Epstein-Barr virus (EBV) replication is normally controlled and provide insight into why certain immunocompromised patients fail to contain it.
METHODS: University students had an average of 7 clinical and virologic evaluations during acute infectious mononucleosis. EBV was quantified in 697 samples of oral wash fluid, whole blood, peripheral blood mononuclear cells (PBMCs), and plasma by a real-time (TaqMan) polymerase chain reaction (qEBV) assay developed in our laboratory.
RESULTS: Twenty of 25 subjects had serologically confirmed primary EBV infection. EBV was cleared from whole blood by a first-order process with a median half-life of 3 days, and its quantity was associated with severity of illness (r2=0.82). Oral shedding persisted at a median of >or=1x104 copies/mL for 32 weeks and was unrelated to severity of illness. Subjects with nonprimary EBV infection shed virus intermittently, and median quantities for all samples became undetectable within 4 weeks.
CONCLUSIONS: Using a novel qEBV assay, we demonstrated that young adults with primary EBV infection rapidly cleared virus from blood but not from the oropharynx. High oral concentrations of EBV in asymptomatic persons who have resumed normal activities support the concept that infectious mononucleosis is most likely acquired by kissing.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16206064     DOI: 10.1086/491740

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  60 in total

1.  Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV.

Authors:  Wei Bu; Gregory M Hayes; Hui Liu; Lorraine Gemmell; David O Schmeling; Pierce Radecki; Fiona Aguilar; Peter D Burbelo; Jennifer Woo; Henry H Balfour; Jeffrey I Cohen
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

2.  Validation of Roche LightCycler Epstein-Barr virus quantification reagents in a clinical laboratory setting.

Authors:  Margaret L Gulley; Hongxin Fan; Sandra H Elmore
Journal:  J Mol Diagn       Date:  2006-11       Impact factor: 5.568

3.  On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis.

Authors:  Vey Hadinoto; Michael Shapiro; Thomas C Greenough; John L Sullivan; Katherine Luzuriaga; David A Thorley-Lawson
Journal:  Blood       Date:  2007-11-08       Impact factor: 22.113

Review 4.  Serological diagnosis of Epstein-Barr virus infection: Problems and solutions.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2012-02-12

5.  Erythema multiforme-like lesions in the course of infectious mononucleosis.

Authors:  Vijay Zawar; Antonio Chuh; Sudhir Sankalecha
Journal:  J Dermatol Case Rep       Date:  2009-11-28

Review 6.  Selected topics on lymphoid lesions in the head and neck regions.

Authors:  Wesley O Greaves; Sa A Wang
Journal:  Head Neck Pathol       Date:  2011-02-03

Review 7.  Progress, prospects, and problems in Epstein-Barr virus vaccine development.

Authors:  Henry H Balfour
Journal:  Curr Opin Virol       Date:  2014-03-15       Impact factor: 7.090

8.  Clinical and virologic manifestations of primary Epstein-Barr virus (EBV) infection in Kenyan infants born to HIV-infected women.

Authors:  Jennifer A Slyker; Corey Casper; Kenneth Tapia; Barbra Richardson; Lisa Bunts; Meei-Li Huang; Elizabeth Maleche-Obimbo; Ruth Nduati; Grace John-Stewart
Journal:  J Infect Dis       Date:  2013-03-14       Impact factor: 5.226

9.  Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.

Authors:  Anne H Blaes; Qing Cao; John E Wagner; Jo-Anne H Young; Daniel J Weisdorf; Claudio G Brunstein
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-14       Impact factor: 5.742

10.  TaqMan Real-Time Quantification of Epstein-Barr Virus in Severe Early Childhood Caries.

Authors:  Sibel Yildirim; Esma Yildiz; Ayhan Kubar
Journal:  Eur J Dent       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.